GTC Biotherapeutics (fka GTCB)

[used to make chicken]

"orders of magnitude" sounds good, but is no longer the case. I believe the difference to be less than one order of magnitude at this time. I'll dig around for some numbers in my spare time.

The key in my mind will be the mABs because the huge doses required compared to something like EPO or NESP. as more of these pass through trials, bioreactor capacity should once again become an issue. Interestingly enough, as huge a market as EPO is responsible for, the world's supply is still produced in roller bottles.